U.S. Markets open in 4 hrs 55 mins

JNJ’s CAR T Cell Therapy and Erdafitinib: Growth Drivers

Daniel Collins
JNJ’s CAR T Cell Therapy and Erdafitinib: Growth Drivers

In May, Johnson & Johnson (JNJ) announced the initiation of its Phase 1b/2 clinical trials. These trials are expected to evaluate JNJ-68284528, a CAR-T cell (chimeric antigen receptor T cell) therapy targeted to combat B cell maturation antigen (or BCMA) in individuals with RRMM (relapsed/refractory multiple myeloma).